ArticlePloS one2018
Comparative genomic analysis of the multispecies probiotic-marketed product VSL#3.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Targeting gut microbiota dysbiosis in inflammatory bowel disease: a systematic review of current evidence.Frontiers in medicine · 2025Pooled it
- Exploring the Potential Probiotic Properties of Bifidobacterium breve DSM 32583-A Novel Strain Isolated from Human Milk.Probiotics and antimicrobial proteins · 2025Article
- Review
- Cell-free supernatant ofFrontiers in microbiology · 2024Article
- Role ofCurrent developments in nutrition · 2023Review
- Microbiome differences related to metformin intolerance among Black individuals with diabetes, a pilot cross-sectional study.Metabolism open · 2023Article
- Acute gastroenteritis-changes to the recommended original oral rehydrating salts: a review.Frontiers in pediatrics · 2023Review
- Development of Resistance to Clarithromycin and Amoxicillin-Clavulanic Acid inMicrobiology spectrum · 2022Article
- The Beneficial Effect of Probiotics Supplementation on Penicillin-Induced Focal Seizure in Rats.Neurochemical research · 2022Article
- Genome Sequence and Assessment of Safety and Potential Probiotic Traits ofMicroorganisms · 2022Article
- Probiotic colonization dynamics after oral consumption of VSL#3Microbiome research reports · 2022Article
- The Recent Trend in the Use of Multistrain Probiotics in Livestock Production: An Overview.Animals : an open access journal from MDPI · 2021Review
- Review
- Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases.World journal of clinical cases · 2020Review
- ProbioticThe EPMA journal · 2019Article
- Development of omics-based protocols for the microbiological characterization of multi-strain formulations marketed as probiotics: the case of VSL#3.Microbial biotechnology · 2019Article
- Comparative genome analysis ofMicrobial genomics · 2019Article
- Short-Term Probiotic Administration Increases Fecal-AntiMicroorganisms · 2019Article
- The Use of Defined Microbial Communities To Model Host-Microbe Interactions in the Human Gut.Microbiology and molecular biology reviews : MMBR · 2019Review
- The Epithelial Barrier Model Shows That the Properties of VSL#3 Depend from Where it is Manufactured.Endocrine, metabolic & immune disorders drug targets · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several probiotic-marketed formulations available for the consumers contain live lactic acid bacteria and/or bifidobacteria. The multispecies product commercialized as VSL#3 has been used for treating various gastro-intestinal disorders. However, like many other products, the bacterial strains present in VSL#3 have only been characterized to a limited extent and their efficacy as well as their predicted mode of action remain unclear, preventing further applications or comparative studies. In this work, the genomes of all eight bacterial strains present in VSL#3 were sequenced and characterized, to advance insights into the possible mode of action of this product and also to serve as a basis for future work and trials. Phylogenetic and genomic data analysis allowed us to identify the 7 species present in the VSL#3 product as specified by the manufacturer. The 8 strains present belong to the species Streptococcus thermophilus, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus helveticus, Bifidobacterium breve and B. animalis subsp. lactis (two distinct strains). Comparative genomics revealed that the draft genomes of the S. thermophilus and L. helveticus strains were predicted to encode most of the defence systems such as restriction modification and CRISPR-Cas systems. Genes associated with a variety of potential probiotic functions were also identified. Thus, in the three Bifidobacterium spp., gene clusters were predicted to encode tight adherence pili, known to promote bacteria-host interaction and intestinal barrier integrity, and to impact host cell development. Various repertoires of putative signalling proteins were predicted to be encoded by the genomes of the Lactobacillus spp., i.e. surface layer proteins, LPXTG-containing proteins, or sortase-dependent pili that may interact with the intestinal mucosa and dendritic cells. Taken altogether, the individual genomic characterization of the strains present in the VSL#3 product confirmed the product specifications, determined its coding capacity as well as identified potential probiotic functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.